Premium
Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health–sponsored workshop
Author(s) -
Roland Lauren T.,
Smith Timothy L.,
Schlosser Rodney J.,
Soler Zachary M.,
Peters Anju T.,
Laidlaw Tanya M.,
Bleier Benjamin S.,
Ramakrishnan Vijay,
Toskala Elina,
Kennedy David W.,
Luong Amber U.
Publication year - 2020
Publication title -
international forum of allergy and rhinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.503
H-Index - 46
eISSN - 2042-6984
pISSN - 2042-6976
DOI - 10.1002/alr.22633
Subject(s) - medicine , chronic rhinosinusitis , nasal polyps , guideline , intensive care medicine , sinusitis , biosimilar , alternative medicine , pathology , surgery
Background Biologic medications are emerging as options for treating chronic rhinosinusitis with nasal polyps (CRSwNP). Several questions remain regarding patient selection, indications, clinical efficacy, and cost effectiveness. Methods In November 2019, a group of physicians and scientists gathered to consider strategies for future studies regarding biologics. During the discussion, gaps in knowledge highlighted a need for a consensus on the present day use of biologics in polyp patients. Results The goal of this guideline is to propose recommendations for the current use of biologics in CRSwNP as new evidence continues to emerge and inform practice. Conclusion We suggest that physicians evaluate patients on an individual basis and closely monitor for improvement due to the high cost and unknown long‐term effects of biologics.